Drug Trial Radar · NCT06928779
Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
Last checked: Nov 19, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Oct 8, 2024
Primary completion
Dec 9, 2024
Study completion Dec 9, 2024
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will compare the pharmacokinetics (PK) of dazucorilant (CORT113176) between participants with normal hepatic function and participants with hepatic impairment.
Conditions
- Hepatic Impairment
Interventions
DazucorilantDrug
Dazucorilant 300 mg (4 X 75 mg) soft gelatin capsules for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve from time zero to the last non-zero concentration (AUC0-t) of dazucorilantTime frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing
- Area under the concentration-time curve from time zero to infinity (extrapolated) (AUC0-inf) of dazucorilantTime frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing
- Maximum observed concentration (Cmax) of dazucorilantTime frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing
- Time to maximum concentration (Tmax) of dazucorilantTime frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing
- Apparent clearance (Cl/F) of dazucorilantTime frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site 2
Rialto, California
Site 1
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.